VLST

AcronymDefinition
VLSTVery Late Stent Thrombosis (medical complication)
VLSTVenturing Leader Specific Training (Boy Scouts of America)
VLSTViral Logic Systems Technology (est. 2004)
VLSTVery Large Space Telescope
VLSTVisual Location in Space-Time
VLSTVital Lies Simple Truths (Daniel Goleman book)
References in periodicals archive ?
sup][6] We needed to evaluate the safety, efficacy, and outcomes of primary PCI with second-generation DES for STEMI due to VLST compared with primary PCI for STEMI due to de novo lesion.
The 608 remaining patients who had only second-generation DES (everolimus-eluting stent and zotarolimus-eluting stent) implanted in the course of the primary PCI for de novo lesion and VLST were included in this retrospective study [Figure 1].
VLST chief executive Martin Simonetti added, We are excited to in-license this promising compound.
Danish pharmaceuticals company Novo Nordisk A/S (OMX Copenhagen: NOVO B) (LSE: NVOB) said on Wednesday (17 December) that it has signed a collaboration agreement with the US biotechnology company VLST Corporation.
Among the four cardiac death events, three of them were attributed to definite or probable late or VLST, although there were no significant differences between two groups.
Antibodies generated by AnaptysBio will be developed and commercialized by VLST, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders.
Tetraphase Pharmaceuticals; TNT Pharma; Vaxart; VentiRx Pharmaceuticals; VLST Corporation
Spirogen Ltd; Syntaxin Ltd; Tetraphase Pharmaceuticals; Vaxart; VentiRx Pharmaceuticals; VLST Corporation; Whitestone Biosciences, Inc.
With the Endeavor DES, the rate of VLST appears to be remarkably and sustainably low - a reassuring record," said steering committee member Dr.
SEATTLE -- Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced that the companies have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilizing VLST's technology platform in the fields of autoimmune and inflammatory disorders.